Abstract
Background: Patients with gastric cancer have a poor prognosis. Therefore, novel treatments as immunotherapy and targeted therapy are extensively studied for improvement of survival. Identification of biomarkers with potential predictive value, such as human epidermal growth factor 2 receptor (HER2), mismatch repair (MMR) deficiency and Epstein-Barr positivity (EBV), is increasingly important. Currently, only testing for HER2 is implemented in clinical guidelines for metastatic gastric cancer. To evaluate the use of potential predictive biomarkers and its current role in treatment, we analysed HER2, MMR and EBV testing in the diagnostic trajectory of gastric cancer patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
